# A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes

> **NCT02846545** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 84 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** Golimumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02846545
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-26
- **Primary completion:** 2019-05-21
- **Final completion:** 2021-01-05
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02846545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02846545, "A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02846545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*